Browse by Research Team

Article

Isolation of neoantigen-specific human T cell receptors from different human and murine repertoires.
Grunert, C., Willimsky, G., Peuker, C.A., Rhein, S., Hansmann, L., Blankenstein, T., Blanc, E., Beule, D., Keller, U., Pezzutto, A. and Busse, A.
Cancers 14 (7): 1842. 6 April 2022

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö., Brzezicha, B., Grunert, C., Kloetzel, P.M., Beier, C., Peuker, C.A., Keller, U., Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S., Heimann, A., Obermayer, B., Ciraolo, E., Althoff, S., Ruß, J., Grunert, C., Busse, A., Bullinger, L., Pezzutto, A., Blankenstein, T., Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Spontaneous non-sustained ventricular tachycardia and premature ventricular contractions and their prognostic relevance in patients with cancer in routine care.
Albrecht, A., Porthun, J., Eucker, J., Coats, A.J.S., von Haehling, S., Pezzutto, A., Karakas, M., Riess, H., Keller, U., Landmesser, U., Haverkamp, W., Anker, S.D. and Anker, M.S.
Cancers 13 (10): 2303. 12 May 2021

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf, G.G., Altmann, B., Ziepert, M., D'Amore, F., Held, G., Greil, R., Tournilhac, O., Relander, T., Viardot, A., Wilhelm, M., Wilhelm, C., Pezzutto, A., Zijlstra, J.M., Van Den Neste, E., Lugtenburg, P.J., Doorduijn, J.K., van Gelder, M., van Imhoff, G.W., Zettl, F., Braulke, F., Nickelsen, M., Glass, B., Rosenwald, A., Gaulard, P., Loeffler, M., Pfreundschuh, M., Schmitz, N. and Trümper, L.
Leukemia 35 (1): 143-155. January 2021

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., Seifarth, W., Spieß, B., Wuchter, P., Krause, S., Kolb, H.J., Neubauer, A., Hossfeld, D.K., Nerl, C., Gratwohl, A., Baerlocher, G.M., Burchert, A., Brümmendorf, T.H., Hasford, J., Hochhaus, A., Saußele, S. and Baccarani, M.
Leukemia 34 (8): 2074-2086. August 2020

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz, S., O'Connor, O.A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Lennard, A., Belada, D., Illés, A., Tobinai, K., Tsukasaki, K., Yeh, S.P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Iyer, S., Zinzani, P.L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T. and Trümper, L.
Lancet 393 (10168): 229-240. 19 January 2019

Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease.
Rieger, K., Günther, U., Erben, U., Kühl, A., Loddenkemper, C., Pezzutto, A., Siegmund, B. and Bojarski, C.
Hematological Oncology 36 (1): 291-298. February 2018

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H.J., Neubauer, A., Hossfeld, D.K., Nerl, C., Gratwohl, A., Baerlocher, G.M., Heim, D., Brümmendorf, T.H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M.C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M.C., Hänel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C.A., Lindemann, H.W., Waller, C.F., Pfreundschuh, M., Spiekermann, K., Berdel, W.E., Müller, L., Edinger, M., Mayer, J., Beelen, D.W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M.J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A. and Hasford, J.
Leukemia 31 (11): 2398-2406. November 2017

Immunomodulatory molecules in renal cell cancer: CD80 and CD86 are expressed on tumor cells.
Flörcken, A., Johannsen, M., Nguyen-Hoai, T., Gerhardt, A., Miller, K., Dörken, B., Pezzutto, A., Westermann, J. and Jöhrens, K.
International Journal of Clinical and Experimental Pathology 10 (2): 1443-1454. 15 February 2017

Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.
Berenstein, R., Nogai, A., Waechter, M., Blau, O., Kuehnel, A., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Dörken, B. and Blau, I.W.
Molecular Carcinogenesis 55 (12): 1927-1939. December 2016

Splenic marginal zone granulocytes acquire an accentuated neutrophil B cell-helper phenotype in chronic lymphocytic leukemia.
Gätjen, M., Brand, F., Grau, M., Gerlach, K., Kettritz, R., Westermann, J., Anagnostopoulos, I., Lenz, P., Lenz, G., Höpken, U.E. and Rehm, A.
Cancer Research 76 (18): 5253-5265. 15 September 2016

CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.
Nguyen-Hoai, T., Pham-Duc, M., Gries, M., Dörken, B., Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 23 (6): 162-167. June 2016

Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma.
Korfel, A., Schlegel, U., Herrlinger, U., Dreyling, M., Schmidt, C., von Baumgarten, L., Pezzutto, A., Grobosch, T., Kebir, S., Thiel, E., Martus, P. and Kiewe, P.
Journal of Clinical Oncology 34 (15): 1757-1763. 20 May 2016

DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.
Floercken, A., Kopp, J., Kölsch, U., Meisel, C., Dörken, B., Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 12 (5): 1117-1123. 3 May 2016

Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.
Flörcken, A., Takvorian, A., Singh, A., Gerhardt, A., Ostendorf, B.N., Dörken, B., Pezzutto, A. and Westermann, J.
Immunology Letters 168 (2): 260-267. December 2015

Apoptosis-susceptibility prolongs the lack of memory B cells in acute leukemic patients after allogeneic hematopoietic stem cell transplantation.
Mensen, A., Oh, Y., Becker, S.C., Hemmati, P.G., Jehn, C., Westermann, J., Szyska, M., Göldner, H., Dörken, B., Scheibenbogen, C., Arnold, R. and Na, I.K.
Biology of Blood and Marrow Transplantation 21 (11): 1895-1906. November 2015

Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
Schneider, T., Flörcken, A., Singh, A., Türkmen, S., Burmeister, T., Anagnostopoulos, I., Pezzutto, A., Dörken, B. and Westermann, J.
Annals of Hematology 94 (8): 1337-1345. August 2015

Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden, F., Marino, S.F., Brand, J., Scheu, S., Kriegel, C., Olal, D., Takvorian, A., Westermann, J., Yilmaz, B., Hinz, M., Daumke, O., Höpken, U.E., Müller, G. and Lipp, M.
Molecular Oncology 9 (7): 1348-1358. August 2015

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV.
Saussele, S., Krauss, M.P., Hehlmann, R., Lauseker, M., Proetel, U., Kalmanti, L., Hanfstein, B., Fabarius, A., Kraemer, D., Berdel, W.E., Bentz, M., Staib, P., de Wit, M., Wernli, M., Zettl, F., Hebart, H.F., Hahn, M., Heymanns, J., Schmidt-Wolf, I., Schmitz, N., Eckart, M.J., Gassmann, W., Bartholomaeus, A., Pezzutto, A., Oppliger Leibundgut, E., Heim, D., Krause, S.W., Burchert, A., Hofmann, W.K., Hasford, J., Hochhaus, A., Pfirrmann, M. and Müller, M.C.
Blood 126 (1): 42-49. 2 July 2015

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F., Koschmieder, S., Slany, R., Schwarzer, R., Saglio, G., Hemmati, P., van Lessen, A., Amini, L., Greese, M., Vagge, E., Burmeister, T., Serra, A., Carson, A., Schwarz, M., Westermann, J., Jundt, F., Doerken, B. and le Coutre, P.
Leukemia & Lymphoma 56 (7): 2105-2113. July 2015

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch, K., Meyer, A.H., Stroux, A., Hirt, C., Keller, U., Viardot, A., Marks, R., Schreiber, S., Pezzutto, A. and Scholz, C.W.
Annals of Hematology 94 (6): 981-988. June 2015

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein, R., Blau, I.W., Suckert, N., Baldus, C., Pezzutto, A., Dörken, B. and Blau, O.
Journal of Experimental & Clinical Cancer Research 34 (1): 55. 22 May 2015

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.
Flörcken, A., Grau, M., Wolf, A., Weilemann, A., Kopp, J., Dörken, B., Blankenstein, T., Pezzutto, A., Lenz, P., Lenz, G. and Westermann, J.
International Journal of Cancer 136 (8): 1814-1826. 15 April 2015

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.
Berenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B. and Blau, I.W.
BMC Cancer 15 (1): 68. 18 February 2015

BCR-ABL1 acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
Neuendorff, N.R., Schwarz, M., Hemmati, P., Tuerkmen, S., Bommer, C., Burmeister, T., Doerken, B., le Coutre, P., Arnold, R. and Westermann, J.
Acta Haematologica 133 (2): 237-241. 2015

Gene gun Her2/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2/neu mouse tumor model.
Nguyen-Hoai, T., Pezzutto, A. and Westermann, J.
Methods in Molecular Biology 1317 : 17-37. 2015

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B cell activation and proliferation.
Heinig, K., Gätjen, M., Grau, M., Stache, V., Anagnostopoulos, I., Gerlach, K., Niesner, R.A., Cseresnyes, Z., Hauser, A.E., Lenz, P., Hehlgans, T., Brink, R., Westermann, J., Dörken, B., Lipp, M., Lenz, G., Rehm, A. and Höpken, U.E.
Cancer Discovery 4 : 1448-1465. December 2014

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT.
Mensen, A., Jöhrens, K., Anagnostopoulos, I., Demski, S., Oey, M., Stroux, A., Hemmati, P., Westermann, J., Blau, O., Wittenbecher, F., Movassaghi, K., Szyska, M., Thomas, S., Dörken, B., Scheibenbogen, C., Arnold, R. and Na, I.K.
Blood 124 (6): 963-972. 7 August 2014

Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans.
Ceko, M., Milenkovic, N., Le Coutre, P., Westermann, J. and Lewin, G.R.
Pain 155 (7): 1222-1228. July 2014

R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.
Kreher, S., Lammer, F., Augustin, D., Pezzutto, A. and Baldus, C.D.
European Journal of Haematology 93 (1): 70-76. July 2014

Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
Jehn, C.F., Böning, L., Kröning, H., Pezzutto, A. and Lüftner, D.
European Journal of Cancer 50 (7): 1269-1275. May 2014

Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.
Singh, A., Schabath, R., Ratei, R., Stroux, A., Klemke, C.D., Nebe, T., Flörcken, A., van Lessen, A., Anagnostopoulos, I., Dörken, B., Ludwig, W.D., Pezzutto, A. and Westermann, J.
Hematological Oncology 32 (1): 16-21. March 2014

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.
Meyer, A.H., Stroux, A., Lerch, K., Eucker, J., Eitle, J., Hohloch, K., Andrzejak, M., Possinger, K., Dörken, B., Pezzutto, A. and Scholz, C.W.
Annals of Oncology 25 (1): 210-215. January 2014

Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia.
Nogai, H., Israel-Willner, H., Zschenderlein, R. and Pezzutto, A.
Case Reports in Hematology 2013 : 958704. 1 August 2013

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert, S., Kempkensteffen, C., Busch, J., Johannsen, M., Gruenwald, V., Zimmermann, K., Floercken, A., Westermann, J., Weinkauf, L., Miller, K. and Keilholz, U.
World Journal of Urology 31 (4): 805-809. August 2013

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
Flörcken, A., Kopp, J., van Lessen, A., Movassaghi, K., Takvorian, A., Jöhrens, K., Möbs, M., Schönemann, C., Sawitzki, B., Egerer, K., Dörken, B., Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 9 (7): 1217-1227. 1 June 2013

Anti-leukemia T cells in AML: TNF-α(+) CD8(+) T cells may escape detection and possibly reflect a stage of functional impairment.
Flörcken, A., van Lessen, A., Terwey, T.H., Dörken, B., Arnold, R., Pezzutto, A. and Westermann, J.
Human Vaccines & Immunotherapeutics 9 (7): 1200-1204. 1 June 2013

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.
Pohla, H., Buchner, A., Stadlbauer, B., Frankenberger, B., Stevanovic, S., Walter, S., Frank, R., Schwachula, T., Olek, S., Kopp, J., Willimsky, G., Stief, C.G., Hofstetter, A., Pezzutto, A., Blankenstein, T., Oberneder, R. and Schendel, D.J.
Molecular Medicine 18 : 1499-1508. 8 February 2013

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz, C.W., Pinto, A., Linkesch, W., Lindén, O., Viardot, A., Keller, U., Hess, G., Lastoria, S., Lerch, K., Frigeri, F., Arcamone, M., Stroux, A., Frericks, B., Pott, C. and Pezzutto, A.
Journal of Clinical Oncology 31 (3): 308-313. 20 January 2013

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity.
Nguyen-Hoai, T., Kobelt, D., Hohn, O., Vu, M.D., Schlag, P.M., Doerken, B., Norley, S., Lipp, M., Walther, W., Pezzutto, A. and Westermann, J.
OncoImmunology 1 (9): 1537-1545. 1 December 2012

CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai, T., Hohn, O., Vu, M.D., Baldenhofer, G., Sayed Ahmed, M.S., Doerken, B., Norley, S., Lipp, M., Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 19 (12): 880-887. December 2012

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer.
Jehn, C.F., Flath, B., Strux, A., Krebs, M., Possinger, K., Pezzutto, A. and Lueftner, D.
Breast Cancer Research and Treatment 136 (3): 789-794. December 2012

Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms.
Schmetzer, O., Moldenhauer, G., Nicolaou, A., Schlag, P., Riesenberg, R. and Pezzutto, A.
Immunology Letters 143 (2): 184-192. 30 April 2012

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Floercken, A., Takvorian, A., Van Lessen, A., Singh, A., Hopfenmueller, W., Doerken, B., Pezzutto, A. and Westermann, J.
Anti-Cancer Drugs 23 (3): 298-302. March 2012

CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
Nguyen-Hoai, T., Baldenhofer, G., Ahmed, M.S., Pham-Duc, M., Gries, M., Lipp, M., Doerken, B., Pezzutto, A. and Westermann, J.
Journal of Gene Medicine 14 (2): 128-137. February 2012

CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai, T., Baldenhofer, G., Sayed Ahmed, M.S., Pham-Duc, M., Vu, M.D., Lipp, M., Doerken, B., Pezzutto, A. and Westermann, J.
Cancer Gene Therapy 19 (1): 69-76. January 2012

Sex differences in the drug therapy for oncologic diseases.
Schmetzer, O. and Floercken, A.
Handbook of Experimental Pharmacology 214 (3): 411-442. 2012

Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells.
Waiczies, H., Lepore, S., Janitzek, N., Hagen, U., Seifert, F., Ittermann, B., Purfürst, B., Pezzutto, A., Paul, F., Niendorf, T. and Waiczies, S.
PLoS ONE 6 (7): e21981. 19 July 2011

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.
Westermann, J., Floercken, A., Willimsky, G., van Lessen, A., Kopp, J., Takvorian, A., Joehrens, K., Lukowsky, A., Schoenemann, C., Sawitzki, B., Pohla, H., Frank, R., Doerken, B., Schendel, D.J., Blankenstein, T. and Pezzutto, A.
Gene Therapy 18 (4): 354-363. April 2011

Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma.
Buchner, A., Pohla, H., Willimsky, G., Frankenberger, B., Frank, R., Baur-Melnyk, A., Siebels, M., Stief, C.G., Hofstetter, A., Kopp, J., Pezzutto, A., Blankenstein, T., Oberneder, R. and Schendel, D.J.
Human Gene Therapy 21 (3): 285-297. March 2010

Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann, J., Hecker, A.C., Floercken, A., Doerken, B. and Pezzutto, A.
Journal of Immunotherapy 32 (6): 667-675. July 2009

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel, K.C., Weidmann, E., Anagnostopoulos, I., Kanz, L., Pezzutto, A. and Subklewe, M.
International Journal of Hematology 88 (4): 434-440. November 2008

Succesful long-term monotherapy with rituximab in a chemotherapy-refractory patient with chronic B-CLL: a case report.
Sturm, I., Oertel, J., Oertel, S., Westermann, J. and Pezzutto, A.
Journal of Medical Case Reports 2 (1): 275. 14 August 2008

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser, F., Seymour, J.F., Kluin-Nelemans, H.C., Grigg, A., Wolf, M., Pfreundschuh, M., Tilly, H., Raemaekers, J., van't Veer, M.B., Milpied, N., Cartron, G., Pezzutto, A., Spencer, A., Reyes, F. and Dreyling, M.
Annals of Oncology 19 (2): 247-253. February 2008

Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study.
Hildebrandt, B., Mueller, C., Pezzutto, A., Daniel, P.T., Doerken, B. and Scholz, C.
BMC Cancer 7 : 185. 3 October 2007

CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.
Westermann, J., Nguyen-Hoai, T., Baldenhofer, G., Höpken, U.E., Lipp, M., Dörken, B. and Pezzutto, A.
Cancer Gene Therapy 14 (6): 523-532. June 2007

Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann, J., Kopp, J., van Lessen, A., Hecker, A.C., Baskaynak, G., le Coutre, P., Doehner, K., Doehner, H., Doerken, B. and Pezzutto, A.
British Journal of Haematology 137 (4): 297-306. May 2007

Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf, K., Nguyen, T.D., Oertel, S., Papp-Vary, M., Trappe, R., Schulzki, A., Pezzutto, A., Riess, H. and Subklewe, M.
Transplant Immunology 17 (3): 203-210. April 2007

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe, M., Sebelin-Wulf, K., Beier, C., Lietz, A., Mathas, S., Doerken, B. and Pezzutto, A.
Human Immunology 68 (3): 147-155. March 2007

1H, 15N and 13C assignments of the cysteine protease inhibitor Chagasin from Trypanosoma cruzi.
Aido-Machado, R., Salmon, D., Diehl, A., Leidert, M., Schmetzer, O., de Lima, A.P.C.A., Scharfstein, J., Oschkinat, H. and Pires, J.R.
Journal of Biomolecular NMR 36 (Suppl) (1): 30. December 2006

Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Subklewe, M., Marquis, R., Choquet, S., Leblond, V., Garnier, J.L., Hetzer, R., Swinnen, L.J., Oertel, S., Papp-Vary, M., Gonzalez-Barca, E., Hepkema, B.G., Schoenemann, C., May, J., Pezzutto, A. and Riess, H.
Transplantation 82 (8): 1093-1100. 27 October 2006

Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.
Sebelin, K., Schulzki, A., Kloetzel, P.M., Doerken, B., Pezzutto, A. and Subklewe, M.
Transplantation 82 (6): 779-787. 27 September 2006

Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis.
Floercken, A., Denecke, T., Kretzschmar, A., Gollasch, H., Reich, G. and Westermann, J.
Onkologie 29 : 382-384. September 2006

Solution structure and backbone dynamics of the Trypanosoma cruzi cysteine protease inhibitor chagasin.
Salmon, D., Aido-Machado, R., Diehl, A., Leidert, M., Schmetzer, O., de Lima, A.P., Scharfstein, J., Oschkinat, H. and Pires, J.R.
Journal of Molecular Biology 357 (5): 1511-1521. 14 April 2006

Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
Westermann, J., Lessen, A., Schlimper, C., Baskaynak, G., Coutre, P., Doerken, B. and Pezzutto, A.
British Journal of Haematology 132 : 32-35. January 2006

CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Westermann, J., Maschmeyer, G., Lessen, A., Doerken, B. and Pezzutto, A.
International Journal of Hematology 82 : 248-250. 1 October 2005

Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.
Stuehmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R.A., Daniel, P.T., Bommert, K., Vassilev, L.T. and Bargou, R.C.
Blood 106 : 3609-3617. 4 August 2005

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
Frankenberger, B., Regn, S., Geiger, C., Noessner, E., Falk, C.S., Pohla, H., Javorovic, M., Silberzahn, T., Wilde, S., Buchner, A., Siebels, M., Oberneder, R., Willimsky, G., Pezzutto, A., Blankenstein, T. and Schendel, D.J.
World Journal of Urology 23 (3): 166-174. 5 July 2005

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger, B., Pohla, H., Noessner, E., Willimsky, G., Papier, B., Pezzutto, A., Kopp, J., Oberneder, R., Blankenstein, T. and Schendel, D.J.
Clinical Cancer Research 11 : 1733-1742. 1 January 2005

Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein.
Schmetzer, O., Moldenhauer, G., Riesenberg, R., Pires, J.R., Schlag, P.M. and Pezzutto, A.
Journal of Immunology 174 (2): 942-952. 1 January 2005

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert, M., Reisinger, I., Srock, S., Humplik, B.I., Reim, C., Kroessin, T., Avril, N., Pezzutto, A. and Munz, D.L.
European Journal of Nuclear Medicine and Molecular Imaging 32 : 1225-1233. 1 January 2005

Trimethoprim-sulfamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of Pneumocystis jiroveci infection.
Jundt, F., Lempert, T., Doerken, B. and Pezzutto, A.
Infection 32 (3): 176-178. 1 June 2004

T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
Westermann, J., Schlimper, C., Richter, G., Mohm, J., Doerken, B. and Pezzutto, A.
British Journal of Haematology 125 (2): 213-216. 1 April 2004

Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
Kim, Y.M., Mapara, M.Y., Down, J.D., Johnson, K.W., Boisgerault, F., Akiyama, Y., Benichou, G., Pelot, M., Zhao, G. and Sykes, M.
Blood 103 : 732-739. 15 January 2004

Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization.
Westermann, J., Nguyen-Hoai, T., Mollweide, A., Richter, G., Schmetzer, O., Kim, H.J., Blankenstein, T., Doerken, B. and Pezzutto, A.
Gene Therapy 11 (13): 1048-1056. 1 January 2004

Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.
Rubio, M.T., Kim, Y.M., Sachs, T., Mapara, M., Zhao, G. and Sykes, M.
Blood 102 : 2300-2307. 15 September 2003

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk, R.F., Benner, A., Hartmann, F., del Valle, F., Weber, C., Pralle, H., Fischer, J.T., Gunzer, U., Pezzutto, A., Weber, W., Grimminger, W., Preiss, J., Hensel, M., Froehling, S., Doehner, K., Haas, R. and Doehner, H.
Leukemia 17 (8): 1521-1528. 1 August 2003

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.
Westermann, J., Koerner, I.J., Kopp, J., Kurz, S., Zenke, M., Doerken, B. and Pezzutto, A.
Cancer Immunology Immunotherapy 52 (3): 194-198. March 2003

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann, J., Reich, G., Kopp, J., Haus, U., Doerken, D. and Pezzutto, A.
Cancer Immunology Immunotherapy 49 : 613-620. 1 January 2001

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells.
Richter, G., Hayden-Ledbetter, M., Irgang, M., Ledbetter, J.A., Westermann, J., Koerner, I., Daemen, K., Clark, E.A., Aicher, A. and Pezzutto, A.
Journal of Biological Chemistry 276 (49): 45686-45693. 1 January 2001

Status of activation of circulating vaccine-elicited CD8+ T cells.
Nielsen, M.B., Monsurro, V., Migueles, S.A., Wang, E., Perez-Diez, A., Lee, K.H., Kammula, U., Rosenberg, S.A. and Marincola, F.M.
Journal of Immunology 165 : 2287-2296. 15 August 2000

Allogeneic vaccination for renal cell carcinoma: development and monitoring.
Pohla, H., Frankenberger, B., Stadlbauer, B., Oberneder, R., Hofstetter, A., Willimsky, G., Pezzutto, A., Doerken, B., Blankenstein, T. and Schendel, D.J.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S83-S87. 1 May 2000

Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.
Westermann, J., Kopp, J., Koerner, I., Richter, G., Qin, Z., Blankenstein, T., Doerken, B. and Pezzutto, A.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S46-S49. 1 May 2000

Characterization of human inducible costimulator ligand expression and function.
Aicher, A., Hayden-Ledbetter, M., Brady, W.A., Pezzutto, A., Richter, G., Magaletti, D., Buckwalter, S., Ledbetter, J.A. and Clark, E.A.
Journal of Immunology 164 (9): 4689-4696. 1 May 2000

Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Panelli, M.C., Riker, A., Kammula, U., Wang, E., Lee, K.H., Rosenberg, S.A. and Marincola, F.M.
Journal of Immunology 164 : 495-504. 1 January 2000

Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells.
Aicher, A., Shu, G.L., Magaletti, D., Mulvania, T., Pezzutto, A., Craxton, A. and Clark, E.A.
Journal of Immunology 163 : 5786-5795. 1 December 1999

CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism.
Daniel, P.T., Scholz, C., Essmann, F., Westermann, J., Pezzutto, A. and Doerken, B.
Experimental Hematology 27 : 1402-1408. 1 September 1999

Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux, S., Richter, G., Becker, C., Pezzutto, A., Doerken, B. and Blankenstein, T.
European Journal of Immunology 29 : 225-234. 1 January 1999

Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "Veto" apoptosis of antibody-targeted cytotoxic T cells.
Daniel, P.T., Kroidl, A., Kopp, J., Sturm, I., Moldenhauer, G., Doerken, B. and Pezzutto, A.
Blood 92 (12): 4750-4757. 15 December 1998

Loss of laminin and of the laminin receptor integrin subunit � in situ correlates with cytokine induced down regulation of alpha 6 on fibroblast-like synoviocytes from rheumatoid arthritis.
Rinaldi, N., Barth, T.F., Weis, D., Schwarz-Eywill, M., Pezzutto, A., Lukoschek, M., Brocai, D. and Brado, B.
Annals of the Rheumatic Diseases 57 : 559-565. 1 September 1998

Dendritic cells for somatic gene therapy.
Westermann, J., Aicher, A. and Pezzutto, A.
Recent Results in Cancer Research 144 : 70-77. 1 January 1998

Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals.
Daniel, P.T., Scholz, C., Westermann, J., Doerken, B. and Pezzutto, A.
Advances in Experimental Medicine and Biology 451 : 173-177. 1 January 1998

Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis.
Daniel, P.T., Kroidl, A., Cayeux, S., Scholz, C., Sturm, I., Blankenstein, T., Pezzutto, A. and Doerken, B.
Advances in Experimental Medicine and Biology 451 : 265-276. 1 January 1998

Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation.
Westermann, J., Aicher, A., Qin, Z., Cayeux, S., Daemen, K., Blankenstein, T., Doerken, B. and Pezzutto, A.
Gene Therapy 5 : 264-271. 1 January 1998

Differential expression and functional behaviour of the ഠand ౠintegrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro.
Rinaldi, N., Weis, D., Brado, B., Schwarz-Eywill, M., Lukoschek, M., Pezzutto, A., Keilholz, U. and Barth, T.F.
Annals of the Rheumatic Diseases 56 : 729-736. 1 December 1997

Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency.
Cayeux, S., Richter, G., Becker, C., Beck, C., Aicher, A., Pezzutto, A., Doerken, B. and Blankenstein, T.
European Journal of Immunology 27 : 1657-1662. 1 January 1997

Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.
Aicher, A., Westermann, J., Cayeux, S., Willimsky, G., Daemen, K., Blankenstein, T., Uckert, W., Doerken, B. and Pezzutto, A.
Experimental Hematology 25 : 39-44. 1 January 1997

Book Section

Humoral immunotherapy and the use of monoclonal antibodies.
Daniel, P.T., Pezzutto, A. and Doerken, B.
In: Textbook of Malignant Haematology. Martin Dunitz Ltd., London, 425-446. 1 January 1999

Book

Taschenatlas der Immunologie : Grundlagen - Labor - Klinik.
Pezzutto, A., Ulrichs, T. and Burmester, G.R.
Thieme, Stuttgart [u.a.]. ISBN 3-13-115382-2 1 January 2007

Review

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber, A.N.R., Cardona Gloria, Y., Çınar, Ö., Reinhardt, H.C., Pezzutto, A. and Wolz, O.O.
Cancer Immunology Immunotherapy 67 (11): 1797-1807. November 2018

Letter

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study.
Rambaldi, A., Iurlo, A., Vannucchi, A.M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M.F., Cambier, N., Marolleau, J.P., Mesa, R.A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica, P., Manzoni, S. and Di Tollo, S.
Leukemia 34 (8): 2234-2237. August 2020

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.
Çakmak-Görür, N., Radke, J., Rhein, S., Schumann, E., Willimsky, G., Heppner, F.L., Blankenstein, T. and Pezzutto, A.
Leukemia 33 (4): 1039-1043. April 2019

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang, N.H., Ogura, M., Castaigne, S., Fayad, L.E., Jerkeman, M., Radford, J., Pezzutto, A., Bondarenko, I., Stewart, D.A., Shnaidman, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P.A., Giné, E. and Ando, K.
British Journal of Haematology 182 (4): 583-586. August 2018

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S., Pastore, A., Scholz, C.W., Forstpointner, R., Pezzutto, A., Bergmann, L., Truemper, L., Finke, J., Keller, U., Ghione, P., Passera, R., Hiddemann, W., Weigert, O., Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016

Editorial

Long-term structured follow-up is essential after curative cancer treatment.
Keilholz, U., Pezzutto, A., Budach, V. and Eggert, A.
Deutsches Aerzteblatt International 111 (1-2): 1-2. 6 January 2014